Furthermore, based on our previous study, which showed that MEDAG promotes EMT and reduces epirubicin sensitivity through the Akt/AMPK/mTOR axis in BC 9, we hypothesized that MEDAG is involved in HG-induced BC progression. The gene discussed is AKT1; the disease is breast cancer.